|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | University of Minnesota - Clinical and Translational Science Institute |
|---|---|
| Collaborator: |
National Institute on Drug Abuse (NIDA) |
| Information provided by: | National Institute on Drug Abuse (NIDA) |
| ClinicalTrials.gov Identifier: | NCT00419731 |
Purpose
The purpose of this study is to compare the effects of bupropion + placebo to bupropion + naltrexone as treatments to help smokers quit.
| Condition | Intervention | Phase |
|---|---|---|
|
Tobacco Use Disorder |
Drug: Bupropion Drug: Bupropion + Naltrexone |
Phase II Phase III |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | Phase II Randomized, Double-Blind Trial of Bupropion Versus Bupropion + Naltrexone for Smoking Cessation |
| Estimated Enrollment: | 120 |
| Study Start Date: | November 2006 |
| Estimated Study Completion Date: | July 2010 |
| Estimated Primary Completion Date: | February 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
Bupropion+Placebo
|
Drug: Bupropion
Sustained-release, 150 mg, q.d., for days 1-3, 150 mg, b.i.d., for balance of 7 weeks. Placebo, 25 mg, q.d., for 7 weeks. |
|
Experimental: 2
Bupropion+Naltrexone
|
Drug: Bupropion + Naltrexone
Bupropion, Sustained-release, 150 mg, q.d., for days 1-3, 150 mg, b.i.d., for balance of 7 weeks. Naltrexone, 25 mg, q.d., for 7 weeks. |
The purpose of this study is to compare the effects of bupropion + placebo to bupropion + naltrexone as treatments to help smokers quit. Bupropion is an FDA-approved medication for smoking cessation that is believed to provide relief from craving and withdrawal through promotion of two neurotransmitter chemicals, dopamine and noradrenaline. Naltrexone is an FDA-approved medication for the treatment of opiate and alcohol dependence, that appears to function through blocking certain opiate receptors in the brain. It is expected that bupropion + naltrexone will produce higher smoking quit rates than bupropion + placebo. Bupropion alone is effective in alleviating some nicotine withdrawal complaints and craving for nicotine. However, bupropion does not reduce the rewarding effects of slips to smoking. Naltrexone alone is not generally effective as a smoking cessation medication, but it does help to reduce the rewarding effects of slips to smoking. Thus, it may help to prevent full relapse to smoking. In addition, naltrexone can help to reduce craving for cigarettes. It is hypothesized that the differing complementary actions of the two drugs will help smokers more than bupropion alone. In addition to examining smoking quit rates, the proposed study will also look at psychological processes that change during smoking cessation including, nicotine withdrawal, nicotine craving, mood, impulsivity, and attention
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Marc E Mooney, Ph.D. | 612-273-9732 | moon0078@umn.edu |
| Contact: Dorothy K Hatsukami, Ph.D. | 612-626-2121 | hatsu001@umn.edu |
| United States, Minnesota | |
| Tobacco Use Research Center, University of Minnesota | Recruiting |
| Minneapolis, Minnesota, United States, 55414 | |
| Contact: Marc E Mooney, Ph.D. 612-273-9732 moon0078@umn.edu | |
| Principal Investigator: Marc E Mooney, Ph.D. | |
| Principal Investigator: | Marc E Mooney, Ph.D. | Univerisity of Minnesota |
More Information
| Responsible Party: | Marc E. Mooney, Ph.D., University of Minnesota |
| ClinicalTrials.gov Identifier: | NCT00419731 History of Changes |
| Other Study ID Numbers: | K01-DA019446-01, K01DA019446-01, DPMC |
| Study First Received: | January 8, 2007 |
| Last Updated: | December 2, 2009 |
| Health Authority: | United States: Federal Government; United States: Institutional Review Board |
|
nicotine smoking addiction |
|
Smoking Tobacco Use Disorder Habits Substance-Related Disorders Mental Disorders Naltrexone Bupropion Narcotic Antagonists Physiological Effects of Drugs Pharmacologic Actions Sensory System Agents |
Peripheral Nervous System Agents Central Nervous System Agents Therapeutic Uses Antidepressive Agents, Second-Generation Antidepressive Agents Psychotropic Drugs Dopamine Uptake Inhibitors Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Neurotransmitter Uptake Inhibitors |